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2 
ABSTRACT 1 
 2 
Patterns of progressive cortical thinning in dementia with Lewy bodies (DLB) 3 
remains poorly understood. We examined spatiotemporal patterns of cortical thinning 4 
and subcortical atrophy over 12 months in DLB (n=13), compared to Alzheimer’s 5 
disease (AD) (n=23) and healthy controls (HC) (n=33). Rates of temporal thinning in 6 
DLB were relatively preserved compared to AD. Volumetric analyses subcortical 7 
changes revealed that the AD group demonstrated significantly increased 8 
hippocampal atrophy (-5.8%) relative to the HC (-1.7%; p<0.001) and DLB groups (-9 
2.5%, p=0.006). Significant lateral ventricular expansion was also observed in AD 10 
(8.9%) compared to HC (4.3%; p<0.001), and DLB (4.7%; p=0.008) at trend level. 11 
There was no significant difference in subcortical atrophy and ventricular expansion 12 
between DLB and HC. In the DLB group, increased rates of cortical thinning in the 13 
frontal and parietal regions were significantly correlated with decline in global 14 
cognition (MMSE) and motor deterioration (UPDRS3) respectively. Overall, AD and 15 
DLB are characterized by different spatiotemporal patterns of cortical thinning over 16 
time. Our findings warrant further consideration of longitudinal cortical thinning as a 17 
potential imaging marker to differentiate DLB from AD.  18 
Keywords: Dementia, Alzheimer’s disease, Lewy bodies, MRI, neuroimaging, 19 
atrophy 20 
21 
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1. INTRODUCTION 1 
 2 
Dementia with Lewy bodies (DLB) is the second leading cause of degenerative 3 
dementia in older people after Alzheimer’s disease (AD), accounting for up to 15% of 4 
cases confirmed at autopsy [1–3]. Because low sensitivity for the diagnosis for DLB 5 
remains a problem [4] , there is a need for the development of reliable imaging 6 
markers to help distinguish DLB from other subtypes of dementia.  7 
 8 
Cortical thickness is increasingly recognized as a more precise parameter of age-9 
associated decline in grey matter compared to the voxel-based morphometry (VBM) 10 
technique [5,6]. In a previous study, we found a greater extent of cortical thinning in 11 
the AD group affecting predominantly temporo-parietal areas whereas DLB was 12 
characterized with cortical thinning in posterior structures [7]. This finding is 13 
consistent with a growing literature of reduced global atrophy in DLB compared to 14 
AD [8], while the preservation of the medial temporal lobe in DLB has been 15 
incorporated as a supportive feature in the revised criteria for the diagnosis of DLB 16 
[9]. 17 
As with our previous investigation, the majority of imaging studies in DLB has been 18 
cross-sectional, and no study to date has investigated the longitudinal progression of 19 
cortical thinning in DLB.  To address this gap in the present literature, our aim in this 20 
study was to compare the progression of cortical thickness over a 12-month period in 21 
AD and DLB, and similarly aged healthy controls (HC). Based on earlier cross-22 
sectional findings [8], we hypothesized that DLB would have significantly lower rates 23 
of cortical thinning compared to AD, particularly in the temporal lobe. 24 
 25 
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2. METHODS 1 
2.1. Subjects, assessment and diagnosis 2 
36 subjects with probable AD [10] and 35 with probable DLB [9] were recruited from 3 
a community dwelling population of patients referred to local Old Age Psychiatry, 4 
Geriatric Medicine or Neurology Services as previously described [11]. Subjects 5 
underwent clinical and neuropsychological evaluations at baseline and follow-up at 1 6 
year. Thirty-five similarly aged control subjects were recruited from relatives and 7 
friends of subjects with dementia or volunteered via advertisements in local 8 
community newsletters. For the purpose of the present study, we included only 9 
subjects with MRI assessments from both baseline and 1-year follow-up. Of the 36 10 
AD subjects, 25 were included after 11 were unable to participate in the follow-up 11 
assessment. Of the 35 DLB subjects, 14 were included after 12 declined to participate 12 
as they or their caregivers felt they were too unwell and 9 subjects had died. However, 13 
there were no significant differences in age, gender, educational level, UPDRS III, 14 
NPI, or cognitive scores between the DLB subjects who dropped out and the DLB 15 
subjects who were included in the present study (Table 2). Of the 35 HC subjects, 33 16 
were included in the present analyses after 2 declined to participate due to other 17 
reasons. The research was approved by the local ethics committee. All subjects or, 18 
where appropriate, their nearest relative, provided written informed consent. At 19 
baseline and follow-up assessments, global cognitive measures included the 20 
Cambridge Cognitive Examination (CAMCOG) [12], which incorporates the Mini-21 
Mental State Examination (MMSE) [13] in addition to a number of subscales 22 
assessing domains including orientation, language, memory, attention, praxis, 23 
calculation, abstract thinking and perception. Visuospatial memory was assessed with 24 
the Brief Visuospatial Memory Test (BVMT) [14]. Motor parkinsonism was 25 
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evaluated with the Unified Parkinson’s Disease Rating Scale Part III (UPDRS-III) 1 
[15]. For subjects with dementia, neuropsychiatric features were examined with the 2 
Neuropsychiatric Inventory [16], and cognitive fluctuations were assessed with the 3 
cognitive fluctuation scale [17]. Functional ability was assessed with the Bristol 4 
Activities of Daily Living Scale (BADLS) [18]. 5 
 6 
2.2. MRI acquisition   7 
Subjects underwent both baseline and repeat MR imaging with a 12-month interval. 8 
At each time point, subjects underwent T1 weighted MR scanning on the same 3T 9 
MRI system using an 8 channel head coil (Intera Achieva scanner, Philips Medical 10 
Systems, Eindhoven, Netherlands). The sequence was a standard T1 weighted 11 
volumetric sequence covering the whole brain (3D MPRAGE, sagittal acquisition, 1 12 
mm isotropic resolution and matrix size of 240 (anterior-posterior) x 240 (superior-13 
inferior) x 180 (right-left); repetition time (TR) = 9.6ms; echo time (TE) = 4.6ms; flip 14 
angle = 8
o
; SENSE factor = 2).  15 
 16 
2.3. Image analysis 17 
Cortical reconstruction and volumetric segmentation of MRI scans were processed on 18 
the same workstation using the Freesurfer 5.3 image analysis suite 19 
(http://surfer.nmr.mgh.harvard.edu/). The technical details are described previously 20 
[19,20]. The initial processing of T1w MRI images, for each subject and each time 21 
point, includes the following steps: removal of non-brain tissue, automated Talairach 22 
transformation, segmentation of the subcortical white matter and deep grey matter 23 
volumetric structures, intensity normalization, tessellation of the grey matter/white 24 
matter boundary, automated topology correction, and surface deformation to 25 
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optimally place the grey matter/white matter and grey matter/cerebrospinal fluid 1 
(CSF) boundaries. The cortical thickness is calculated as the closest distance from the 2 
grey/white matter boundary to the grey/CSF boundary at each vertex. All surface 3 
models in our study were inspected for accuracy and manual corrections were 4 
performed in the event of tissue misclassification / white matter errors. However, 3 5 
subjects (2 AD, 1 DLB) still had extensive pial/white matter surface errors and were 6 
excluded. The dataset for all subsequent analyses comprised of 33 HC, 23 AD, and 13 7 
DLB. 8 
 9 
Subsequently, for the longitudinal processing, an unbiased within-subject template 10 
space [21] was created using robust, inverse consistent registration [22]. Several 11 
processing steps, such as skull stripping, Talairach transformations, atlas registration, 12 
as well as spherical surface maps and parcellations were then initialized with common 13 
information from the within-subject template, significantly increasing reliability and 14 
statistical power [23]. The cortical thickness maps were smoothed using a 15-mm full 15 
width at half maximum Gaussian kernel to reduce local variations in the 16 
measurements.  17 
In addition, the following volumetric measures at both time-points were automatically 18 
obtained using Freesurfer: total intracranial volume, lateral ventricles, and 7 19 
subcortical structures including the thalamus, caudate, putamen, pallidum, 20 
hippocampus, amygdala, and the nucleus accumbens.  21 
 22 
2.4. Statistical analyses 23 
Demographic and clinical measures 24 
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Statistical analyses were performed with the STATA13 (http://www.stata.com/) 1 
software. The distribution of continuous variables was tested for normality using the 2 
Skewness-Kurtosis test and visual inspection of histograms. Parametric data were 3 
assessed using either t-tests or analysis of variance (ANOVA) for continuous 4 
variables. For non-parametric data, Kruskal-Wallis was used. χ2 tests were used to 5 
examine differences between categorical measures. For each test statistic, a two-tailed 6 
probability value of < 0.05 was regarded as significant.   7 
 8 
Cortical thickness comparisons 9 
For each hemisphere, vertex-wise comparisons of percent change of cortical thickness 10 
(PcCTh) among the subject groups were performed using the longitudinal two stage 11 
general linear model in Freesurfer [23]. The PcCTh was the dependent factor and the 12 
diagnostic group was the independent factor. Additionally, we examined the 13 
correlations of PcCTh with cognitive decline (baseline score – follow-up score. To 14 
assess the involvement of PcCTH in disease severity, we assessed correlations with 15 
change scores of the UPDRS. In all imaging analyses, age and gender were included 16 
as nuisance covariates, and Family Wise Error (FWE) cluster-wise correction using 17 
Monte Carlo simulations with 10,000 iterations were applied to correct for multiple-18 
comparisons [24].  19 
 20 
Longitudinal atrophy of subcortical structures 21 
To reduce the number of comparisons, we derived a total volume for each structure by 22 
combining the volumes from both hemispheres.  For each subject, we first calculated 23 
the absolute difference in volumes between both times [(volume follow-up – volume 24 
baseline)], before dividing by the volume at baseline [(volume follow-up – volume baseline) / 25 
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volume baseline] to quantify the amount of atrophy with respect to baseline, before 1 
multiplying by 100 to derive a percentage change score:  [(volume follow-up – volume 2 
baseline) / volume baseline] * 100%. Subsequently, group differences in percentage change 3 
of subcortical volumes were tested with analysis of covariance (ANCOVA) 4 
controlling for age, gender, and the average of total intracranial volumes at both time-5 
points. Post-hoc Tukey-Kramer pairwise comparisons were subsequently tested 6 
between each group. 7 
 8 
3. Results 9 
Subject characteristics 10 
The demographic and clinical data for dementia and control subjects are summarized 11 
in Table 1. Subject groups were well matched for age, gender, and educational level, 12 
and there was no difference in inter-scan intervals among all subject groups (p=0.21). 13 
As expected, the DLB group had significantly higher UPDRS scores than the AD and 14 
HC groups at both time-points. Functional ability (BADLS) was similar in DLB and 15 
AD (p=0.23). Disease duration was comparable in both DLB (52.2 months) and AD 16 
(51.8 months; p=0.96), and the proportion of subjects on cholinesterase inhibitors was 17 
also similar (p=0.23). There were no significant differences in changes of NPI 18 
(p=0.50), CogFluct (p=0.52), between DLB and AD. 19 
 20 
Longitudinal analyses of cognitive decline in DLB and AD 21 
AD and DLB did not differ on global cognitive measures such as MMSE and 22 
CAMCOG at baseline or follow-up. Although both DLB and AD performed poorer 23 
over time, the decline in global cognition did not differ between groups. BVMT 24 
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scores were similar for both groups at baseline and follow-up, including change 1 
scores. 2 
 3 
Comparisons of longitudinal cortical thinning: AD vs HC 4 
Compared to HC, the AD subjects had significantly greater PcCTh in the bilateral 5 
frontal and temporo-parietal cortices: left precuneus, left rostral middle frontal gyrus, 6 
left isthmus cingulate, left temporal pole, left superior parietal gyrus, left superior 7 
frontal gyrus, left inferior parietal gyrus, left middle temporal gyrus, left caudal 8 
middle frontal gyrus   left cuneus, right superior parietal gyrus, right precuneus, right 9 
superior frontal gyrus, right paracentral gyrus and right  middle temporal gyrus. 10 
Compared to AD, no increased rates of cortical thinning was found in the HC group 11 
(Figure 1; Table e-1; FWE Monte Carlo cluster-wise corrected). 12 
 13 
Comparisons of longitudinal cortical thinning: AD vs DLB 14 
Compared to DLB, the AD subjects had significantly greater PcCTh in the left middle 15 
and superior temporal gyrus, extending to the left lingual gyrus. No increased 16 
progressive cortical thinning was found in the DLB group compared to AD (Figure 1; 17 
Table e-1; FWE Monte Carlo cluster-wise corrected). 18 
 19 
Comparisons of longitudinal cortical thinning: DLB vs HC 20 
There were no significant differences in PcCTh in any regional areas between the 21 
DLB and HC groups. 22 
 23 
Clinical and cognitive associations of cortical thinning  24 
The anatomical results for the vertex-wise correlational analyses are displayed in 25 
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10 
Figure 2; Table e-2; controlled for age and gender and FWE Monte Carlo cluster-wise 1 
corrected. In the DLB group, increased PcCTH in the left frontal lobe was 2 
significantly correlated with decline in MMSE scores, CAMCOG Orientation and 3 
Expressive Language performances. Decline in UPDRS was also significantly 4 
correlated with increased rates of thinning in the right superior parietal region.  In the 5 
AD group, increased PcCTH in the bilateral frontal regions were significantly 6 
correlated with decline in BVMT scores. No significant correlations between rates of 7 
cortical thinning and cognitive decline were demonstrated in the HC group. 8 
 9 
Longitudinal comparisons of subcortical atrophy and ventricular expansion 10 
Table 3 and Figure 3 show the percentage change in subcortical volumes between 11 
baseline and follow-up. After Bonferroni correction for multiple comparisons, the AD 12 
group demonstrated significantly increased longitudinal hippocampal atrophy (-5.8%) 13 
relative to the HC (-1.7%; p<0.001) and DLB groups (-2.5%, p=0.006). Significant 14 
lateral ventricular expansion was also observed in AD (8.9%) compared to HC (4.3%; 15 
p<0.001), and DLB (4.7%; p=0.008) at trend level. There was no significant 16 
difference in subcortical atrophy and ventricular expansion between DLB and HC. 17 
 18 
4. Discussion 19 
Previous longitudinal studies in DLB have focused on the assessment of global brain 20 
measures such as whole brain atrophy rates, yielding somewhat conflicting results. 21 
O’Brien and colleagues found no significant differences in whole brain atrophy rates 22 
between AD and DLB [25]. In contrast, another study with pathological confirmation 23 
of diagnosis revealed significantly greater global atrophy rates in AD compared to 24 
DLB [26]. To our knowledge, this is the first study to evaluate the topographical 25 
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differences in the progression of cortical thinning between DLB and AD. The main 1 
findings are: (i) DLB and AD are characterized by distinct spatial and temporal 2 
patterns of cortical thinning. Consistent with our a priori hypothesis, the temporal 3 
lobe showed significantly greater cortical thinning in AD compared to DLB over the 4 
follow-up period; (ii) regional cortical thinning over time was correlated with 5 
cognitive decline in both AD and DLB groups; (iii) significantly greater loss of 6 
hippocampal volume and lateral ventricular expansion over 1 year was also observed 7 
in the AD group. 8 
 9 
Firstly, the present longitudinal findings should be interpreted in light of the baseline 10 
comparison [7]. Compared to similarly aged HC, we have previously reported that 11 
AD was characterized by cortical thinning in the temporo-parietal cortices extending 12 
into the frontal lobes while a milder degree of cortical thinning in the parietal regions 13 
was evident in DLB. Furthermore, cortical thickness of the left temporal lobe was 14 
relatively preserved in DLB compared to AD at baseline. As such, it is noteworthy 15 
that our present longitudinal study has revealed a similar spatial pattern of accelerated 16 
thinning in the cortical regions that were already thinner in AD compared to HC and 17 
DLB at baseline.  18 
 19 
At present, the longitudinal progression of cortical thinning in DLB is relatively 20 
unknown. Moreover, the cellular mechanisms through which alpha-synuclein 21 
pathology – the characteristic hallmark of Lewy body disease – contributes to 22 
neurodegeneration remains poorly understood [27]. Increasing in vitro evidence also 23 
suggests that alpha-syunclein is not a direct causative factor of neurodegeneration. 24 
Rather, it triggers a series of secondary molecular processes that eventually leads to 25 
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neuroinflammation, disruption of neurotransmitters, and eventually cell loss [27,28]. 1 
Consistent with this view, we found no differences in the rates of regional cortical 2 
thinning between DLB and HC over 12 months. Although it is possible that our 3 
negative finding might represent a Type-II error due to the relatively small sample 4 
size of DLB (n=13) and short duration of follow-up (1 year), corroborative evidence 5 
have come from previous studies. A larger study has found similar global and 6 
regional brain atrophy rates in pathologically confirmed DLB (n = 20) and HC (n = 7 
15) subjects  over a long follow-up period of 2 years [29]. In addition, using a 8 
Boundary Shift Integral method, Whitwell and colleagues (2007) also reported 9 
minimal global atrophy rates in DLB (n = 9) compared to HC (n = 25). Similar 10 
patterns of atrophy rates have also been reported in subjects with Parkinson’s disease 11 
(PD), another Lewy body disease [30,31]. These convergent findings, despite 12 
methodological differences and sampling (clinical and autopsy confirmation), support 13 
the view that alpha-synuclein pathology – a major constituent of Lewy bodies – has 14 
limited direct involvement in cerebral atrophy.  This notion is also consistent with 15 
evidence demonstrating a strong correlation between hippocampal atrophy and β-16 
amyloid plaques and neurofibrillary tangles but not synuclein pathology [32]. 17 
 18 
Compared to AD, DLB was characterized by a significantly slower rate of temporal  19 
thinning compared to AD. It is well-established that the relative preservation of the 20 
MTL in DLB compared to AD is recognized as the most consistent structural MRI 21 
finding at the cross-sectional level [8], and is in keeping with the different 22 
neuropsychological profiles of both groups. Considered with our baseline observation 23 
of reduced temporal thickness in AD [7], the present findings extend the literature by 24 
elucidating the differential trajectories of temporal thinning in both conditions over 25 
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time, thereby validating the inclusion of medial temporal lobe preservation as a 1 
supportive biomarker for the clinical diagnosis of DLB [9]. While the diagnostic 2 
value of FP-CIT for DLB has been established to be the “gold standard” in the clinical 3 
community [33], there are clinical benefits to be gained with multimodal imaging (i.e. 4 
integrating SPECT and MRI in conjunction).  In terms of improving accuracy in 5 
differential diagnosis, MRI striatal volumetric data have been combined with occipital 6 
perfusion SPECT to distinguish subjects with mild DLB from subjects with mild AD 7 
with a high degree of sensitivity and specificity [34].  8 
 9 
The clinical implications of cortical thinning in DLB are still poorly understood. Our 10 
correlational analyses of the UPDRS change scores among the DLB subjects revealed 11 
a significant association between increased thinning in the superior parietal cortex and 12 
greater motor deterioration. Our findings are in accord with recent VBM studies 13 
demonstrating significant atrophy of the parietal cortex in PD subjects presenting with 14 
freezing of gait compared to PD subjects without freezing symptoms [35,36]. In 15 
addition, white matter hyperintensities in the parietal lobe has been linked to impaired 16 
balance and postural support [37].  Taken together, these findings fits within the 17 
framework that the superior parietal lobe is part of the motor system involved in 18 
sensorimotor integration. 19 
The frontal lobe was also involved with cognitive decline in the DLB group. 20 
Increased thinning in the superior frontal regions was associated with greater decline 21 
in MMSE, an index of global cognition. In addition, increased thinning in the left 22 
rostral middle frontal regions was correlated with both the orientation and language 23 
components of the CAMCOG assessment. Similarly, reductions in prefrontal volumes 24 
have been correlated with attentional deficits [38]. Despite the small sample size in 25 
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our study, the potential of the frontal lobe as a plausible biomarker for cognitive 1 
impairment in DLB should be established further in a larger cohort of DLB subjects. 2 
 3 
Increased cortical thinning over 1 year in AD relative to HC was found in the 4 
temporo-parietal areas extending to the frontal regions. Our results are thus in 5 
agreement with earlier studies demonstrating that AD is associated with progressive 6 
loss of whole brain volumes, particularly in the medial temporal structures [25]. 7 
Increased rates of cortical thinning were also found in the precuneus and the isthmus 8 
of the cingulate gyrus. Both structures are involved in the default mode network, 9 
which has been found to be impaired in AD [39]. Indeed, the precuneus has been 10 
implicated in episodic memory [40] while the posterior cingulate projects strongly to 11 
the enthorinal and parahippocampal cortices, both of which are among the earliest 12 
sites of pathological changes in AD [41]. 13 
 14 
Consistent with the differential patterns of progressive cortical thinning in AD and 15 
DLB, our longitudinal analyses of subcortical changes also revealed significantly 16 
faster atrophy in the AD group, particularly in the hippocampus, and the thalamus 17 
albeit at trend level. The finding of increased ventricular expansion in AD compared 18 
to HC and DLB also agrees with previous studies [42].  19 
 20 
The major strengths of the study include the comprehensive neuropsychological 21 
assessment and a well-characterized group of probable DLB and AD patients. In 22 
addition, all the groups were matched for age, gender, and educational level. The 23 
longitudinal design, a rarity in the DLB imaging literature, allowed us to address 24 
unanswered questions related to the progression and clinical implications of cortical 25 
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thinning in Lewy body dementia. Some potential limitations of this study include the 1 
lack of neuropathological verification of AD and DLB, as subject groups were based 2 
on clinical diagnosis, though this is an inherent limitation of all ante-mortem imaging 3 
studies. Furthermore, we have previously demonstrated good agreement between 4 
clinical and pathological diagnosis using the consensus clinical diagnostic method 5 
adopted here [43]. Attrition of subjects is also a common drawback in longitudinal 6 
studies. Less than half (n=14) of the originally recruited DLB subjects (n=35) 7 
returned for a follow-up assessment due to disease progression including 9 deaths. 8 
However, they did not differ from those who were unable to complete the 12-month 9 
assessment (n=21) in age or measures of global cognition, neuropsychiatric features 10 
or motor parkinsonism (Table 2). Finally, to minimize the number of comparisons 11 
between the DLB, AD and HC groups, we have summed the left and right 12 
hemispheric measures of each subcortical structure. Although there is no evidence to 13 
indicate systematic laterality of subcortical changes in AD and DLB, our combined 14 
volumes for each structure might have resulted in a loss of potential information about 15 
asymmetrical disease-related changes. 16 
 17 
5. Conclusion 18 
In accordance with our hypothesis, faster thinning over 1 year was found in the 19 
temporal lobe in AD relative to DLB. Besides validating the inclusion of the medial 20 
temporal lobe as a supportive biomarker in the revised diagnostic criteria for DLB, 21 
our findings also highlight the clinical utility of longitudinal cortical thinning as a 22 
complementary imaging marker to differentiate DLB from AD. Greater cortical 23 
thinning could exert deleterious effects on global cognitive decline and was associated 24 
with increasing motor severity in DLB. However, our finding of similar rates of 25 
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cortical thinning in DLB and HC underscores the ongoing need to develop other 1 
surrogate biomarkers of disease progression in DLB. 2 
 3 
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Table 1. Demographics, clinical and neuropsychological measures. 1 
Values expressed as Mean  1SD. § χ2– DLB, AD, Controls; *ANOVA – HC, DLB, 2 
AD. 
k 
Kruskal-Wallis test. 
w
 Wilcoxon rank-sum test – AD and DLB.  † Student’s t-3 
test – AD and DLB.  Abbreviations: DLB = dementia with Lewy bodies; AD = 4 
Alzheimer’s disease; HC = Healthy control; UPDRS III = Unified Parkinson’s 5 
Disease Rating Scale, Part III; NPI Total = Neuropsychiatry Inventory; CogFluct = 6 
Cognitive Fluctuation Scale; MMSE = Mini-Mental State examination; CAMCOG = 7 
 
 
 
HC 
 
DLB 
 
AD 
 
p value 
     
n 33 13 23  
Gender (m:f) 20:13 12:1 13:10 χ2=5.28, 0.07§ 
Age (yrs) 76.7 ± 5.3 77.0 ± 8.3 76.5 ± 5.4 F2,68=0.03, p=0.97
*
 
Education (yrs) 11.8 ± 2.6 10.6 ± 1.9 11.3 ± 3.8 p=0.16
k 
Disease duration (mths)  52.2 ± 20.4 51.8 ± 26.5 p=0.96
†
 
ChEI (%)  76.92 91.30 χ2=1.44, p=0.23§ 
BADL  17.41 ± 10.17 14.09 ± 7.87 p=0.23
 w
 
UPDRS 
   Baseline 1.9 ± 1.8 27.7 ± 8.0 4.7 ± 4.1 p<0.01
k
 
   Follow-up 2.1 ± 2.0 32.6 ± 13.2 5.7 ± 4.8 p<0.01
k
 
   Change -0.2 ± 2.0 -4.9 ± 8.4 -1.0 ± 2.4 p=0.09
w
 
NPI Total  
  Baseline  21.1 ± 16.8 19.4 ± 12.4 p=0.81
w
 
  Follow-up  24.8 ± 14.9 19.7 ± 15.0 p=0.30
w
 
   Change  -3.7 ± 17.4 -0.3 ± 11.8 p=0.50
t
 
CogFluct  
   Baseline  8.1 ± 3.4 2.8 ± 3.6 p<0.01
w
 
   Follow-up  7.8 ± 5.4 1.8 ± 3.3 p<0.01
w
 
   Change  -0.1 ± 4.4 1.0 ± 4.6 p=0.52
t
 
MMSE     
   Baseline 29.2 ± 0.9 21.3 ± 6.3 20.9 ± 4.0 p=0.80
†
 
   Follow-up 29.2 ± 0.9 19.8 ± 5.8 18.8 ± 4.2 p=0.60
†
 
   Change -0.1 ± 1.0 2.6 ± 2.9 2.0 ± 3.2 P=0.63
†
 
CAMCOG 
  Baseline 97.8 ± 3.3 69.9 ± 18.0 69.2 ± 11.3  p=0.90
†
 
  Follow-up 98.6 ± 2.8 66.8 ± 17.9 62.2 ± 14.4 p=0.42
†
 
  Change -0.8 ± 2.50 5.8 ± 10.8 7.0 ± 10.2 p=0.74
†
 
BVMT-Total     
  Baseline 18.9 ± 6.7 6.23 ± 6.7 4.2 ± 2.7 p= 0.51
w
 
  Follow-up 21.9 ± 5.8 7.8 ± 7.7 5.2 ± 2.6 p=0.51
 w
 
  Change -3.0 ± 5.3 -0.1 ± 4.5 -1.0 ± 2.7 
p=0.48
† 
Interscan interval (days) 370.9 ± 13.3 379.1 ± 18.8 379.6 ± 17.8 p=0.21
k
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Cambridge Cognitive Examination; BADLS =  Bristol Activities of Daily Living 1 
Scale. 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
 26 
 27 
 28 
 29 
 30 
 31 
 32 
 33 
Table 2. Demographics and clinical characteristics of DLB subjects. 34 
 35 
Values expressed as Mean  1SD 36 
§
 χ2– Chi-Square test; w Wilcoxon rank-sum test.  † Student’s t-test.  37 
Abbreviations: DLB = dementia with Lewy bodies; UPDRS III = Unified Parkinson’s 38 
Disease Rating Scale, Part III; NPI Total = Neuropsychiatry Inventory; CogFluct = 39 
Cognitive Fluctuation Scale; MMSE = Mini-Mental State examination; CAMCOG = 40 
Cambridge Cognitive Examination. 41 
  42 
 DLB 
dropped-out  
DLB 
returned 
P value 
n 21 14  
Gender (m:f) 14:7 13:1 χ2=3.3, 0.07§ 
Age (yrs) 79.1  6.2 77.2  8.0 p=0.43
†
 
Education (yrs) 11.0  3.0 10.5  1.9 p=0.69
w
 
UPDRS 25.1  12.3 27.2  7.9 p=0.58
†
 
NPI Total 21.4  18.1 21.5  16.1 p=0.70
w
 
CogFluct 4.6  3.3 8.4  3.4 p<0.01
†
 
MMSE 19.7  4.7 21.2  6.0 p=0.42
†
 
CAMCOG 66.2  14.0 69.9  17.3 p=0.49
†
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Subcortical 
structures & 
lateral 
ventricle 
Percentage of change 
a 
 
Group comparisons of longitudinal 
subcortical atrophy 
b 
HC DLB AD 
AD vs 
HC 
DLB vs 
HC AD vs DLB 
Thalamus -0.87% -2.01% -2.41% 0.001* 0.06 0.82 
Caudate -1.47% -3.77% -3.20% 0.23 0.21 0.93 
Putamen -0.39% -0.30% -0.82% 0.80 0.99 0.82 
Pallidum -0.04% -0.58% 0.20% 0.97 0.52 0.45 
Hippocampus -1.70% -2.51% -5.76% <0.001** 0.90 0.006** 
Amygdala -2.41% -6.25% -4.80% 0.17 0.11 0.84 
Accumbens -0.33% -1.00% -2.05% 0.87 0.94 0.76 
Lateral 
ventricle + 4.29% + 4.70% + 8.91% <0.001** 0.990 0.008* 
 1 
Table 3. Comparisons of longitudinal atrophy in subcortical structures and 2 
lateral ventricle expansion between groups.  3 
a 
Percentage of change in volumes between baseline and follow-up, measured 4 
according to baseline.  5 
b  
Group-comparisons were performed with ANCOVA, correcting for age, gender and 6 
the average total intracranial volume, followed by post-hoc Tukey-Kramer pairwise 7 
comparisons.  8 
* Significant difference at standard threshold of p < 0.05 without correction for 9 
multiple comparisons. 10 
** Significant difference between groups after Bonferroni correction for multiple 11 
comparisons. 12 
Abbreviations: DLB, dementia with Lewy bodies; AD, Alzheimer’s disease; HC, 13 
Healthy control. 14 
 15 
 16 
  17 
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 1 
Figure 1. Vertex-wise comparisons of progressive cortical thinning between (A) 2 
AD and HC, (B) AD and DLB. Results were corrected using family-wise error 3 
correction with Z Monte Carlo simulation (10,000) iterations and thresholded at a 4 
corrected P value of 0.01 (Z=2.0). Age and sex were included as nuisance covariates. 5 
The color bar shows the logarithmic scale of p values (-log10).  6 
Abbreviations: DLB = dementia with Lewy bodies; AD = Alzheimer’s disease; HC = 7 
healthy controls; Lh = left hemisphere; Rh = right hemisphere. 8 
  9 
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 1 
 2 
Figure 2. Vertex-wise correlations between percent of cortical thinning and 3 
longitudinal decline in (A) BVMT total scores in AD, (B) MMSE in DLB, (C) 4 
CAMCOG-Expressive Language in DLB, (D) CAMCOG-orientation scores in 5 
DLB, (E) UPDRS progression in DLB. Results were corrected using family-wise 6 
error correction with Z Monte Carlo simulation (10,000) iterations and thresholded at 7 
a corrected P value of 0.01 (Z=2.0). The color bar shows the logarithmic scale of p 8 
values (-log10). Abbreviations: DLB = dementia with Lewy bodies; AD = Alzheimer’s 9 
disease; Lh = left hemisphere; Rh = right hemisphere; MMSE = Mini-Mental State 10 
examination; CAMCOG = Cambridge Cognitive Examination; BVMT = Brief 11 
Visuospatial Memory Test; UPDRS = Unified Parkinson’s Disease Rating Scale. 12 
 13 
 14 
 15 
 16 
 17 
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 1 
 2 
Figure 3. Longitudinal atrophy in subcortical structures and lateral ventricle 3 
expansion.  4 
* Significant difference at standard threshold of p < 0.05 without correction for 5 
multiple comparisons. 6 
** Significant difference between groups after Bonferroni correction for multiple 7 
comparisons. 8 
Abbreviations: DLB, dementia with Lewy bodies; AD, Alzheimer’s disease; HC, 9 
Healthy control. 10 
  11 
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